Prospects for immunisation against Marburg and Ebola viruses

Thomas Geisbert, Daniel G. Bausch, Heinz Feldmann

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

For more than 30 years the filoviruses, Marburg virus and Ebola virus, have been associated with periodic outbreaks of hemorrhagic fever that produce severe and often fatal disease. The filoviruses are endemic primarily in resource-poor regions in Central Africa and are also potential agents of bioterrorism. Although no vaccines or antiviral drugs for Marburg or Ebola are currently available, remarkable progress has been made over the last decade in developing candidate preventive vaccines against filoviruses in nonhuman primate models. Due to the generally remote locations of filovirus outbreaks, a single-injection vaccine is desirable. Among the prospective vaccines that have shown efficacy in nonhuman primate models of filoviral hemorrhagic fever, two candidates, one based on a replication-defective adenovirus serotype 5 and the other on a recombinant VSV (rVSV), were shown to provide complete protection to nonhuman primates when administered as a single injection. The rVSV-based vaccine has also shown utility when administered for postexposure prophylaxis against filovirus infections. A VSV-based Ebola vaccine was recently used to manage a potential laboratory exposure.

Original languageEnglish (US)
Pages (from-to)344-357
Number of pages14
JournalReviews in Medical Virology
Volume20
Issue number6
DOIs
StatePublished - Nov 2010

Fingerprint

Marburgvirus
Ebolavirus
Immunization
Vaccines
Primates
Ebola Vaccines
Disease Outbreaks
Fever
Biological Warfare Agents
Central Africa
Injections
Adenoviridae
Antiviral Agents
Infection

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Prospects for immunisation against Marburg and Ebola viruses. / Geisbert, Thomas; Bausch, Daniel G.; Feldmann, Heinz.

In: Reviews in Medical Virology, Vol. 20, No. 6, 11.2010, p. 344-357.

Research output: Contribution to journalArticle

Geisbert, Thomas ; Bausch, Daniel G. ; Feldmann, Heinz. / Prospects for immunisation against Marburg and Ebola viruses. In: Reviews in Medical Virology. 2010 ; Vol. 20, No. 6. pp. 344-357.
@article{afb31e300ec14bf9881936dd8d5882a0,
title = "Prospects for immunisation against Marburg and Ebola viruses",
abstract = "For more than 30 years the filoviruses, Marburg virus and Ebola virus, have been associated with periodic outbreaks of hemorrhagic fever that produce severe and often fatal disease. The filoviruses are endemic primarily in resource-poor regions in Central Africa and are also potential agents of bioterrorism. Although no vaccines or antiviral drugs for Marburg or Ebola are currently available, remarkable progress has been made over the last decade in developing candidate preventive vaccines against filoviruses in nonhuman primate models. Due to the generally remote locations of filovirus outbreaks, a single-injection vaccine is desirable. Among the prospective vaccines that have shown efficacy in nonhuman primate models of filoviral hemorrhagic fever, two candidates, one based on a replication-defective adenovirus serotype 5 and the other on a recombinant VSV (rVSV), were shown to provide complete protection to nonhuman primates when administered as a single injection. The rVSV-based vaccine has also shown utility when administered for postexposure prophylaxis against filovirus infections. A VSV-based Ebola vaccine was recently used to manage a potential laboratory exposure.",
author = "Thomas Geisbert and Bausch, {Daniel G.} and Heinz Feldmann",
year = "2010",
month = "11",
doi = "10.1002/rmv.661",
language = "English (US)",
volume = "20",
pages = "344--357",
journal = "Reviews in Medical Virology",
issn = "1052-9276",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Prospects for immunisation against Marburg and Ebola viruses

AU - Geisbert, Thomas

AU - Bausch, Daniel G.

AU - Feldmann, Heinz

PY - 2010/11

Y1 - 2010/11

N2 - For more than 30 years the filoviruses, Marburg virus and Ebola virus, have been associated with periodic outbreaks of hemorrhagic fever that produce severe and often fatal disease. The filoviruses are endemic primarily in resource-poor regions in Central Africa and are also potential agents of bioterrorism. Although no vaccines or antiviral drugs for Marburg or Ebola are currently available, remarkable progress has been made over the last decade in developing candidate preventive vaccines against filoviruses in nonhuman primate models. Due to the generally remote locations of filovirus outbreaks, a single-injection vaccine is desirable. Among the prospective vaccines that have shown efficacy in nonhuman primate models of filoviral hemorrhagic fever, two candidates, one based on a replication-defective adenovirus serotype 5 and the other on a recombinant VSV (rVSV), were shown to provide complete protection to nonhuman primates when administered as a single injection. The rVSV-based vaccine has also shown utility when administered for postexposure prophylaxis against filovirus infections. A VSV-based Ebola vaccine was recently used to manage a potential laboratory exposure.

AB - For more than 30 years the filoviruses, Marburg virus and Ebola virus, have been associated with periodic outbreaks of hemorrhagic fever that produce severe and often fatal disease. The filoviruses are endemic primarily in resource-poor regions in Central Africa and are also potential agents of bioterrorism. Although no vaccines or antiviral drugs for Marburg or Ebola are currently available, remarkable progress has been made over the last decade in developing candidate preventive vaccines against filoviruses in nonhuman primate models. Due to the generally remote locations of filovirus outbreaks, a single-injection vaccine is desirable. Among the prospective vaccines that have shown efficacy in nonhuman primate models of filoviral hemorrhagic fever, two candidates, one based on a replication-defective adenovirus serotype 5 and the other on a recombinant VSV (rVSV), were shown to provide complete protection to nonhuman primates when administered as a single injection. The rVSV-based vaccine has also shown utility when administered for postexposure prophylaxis against filovirus infections. A VSV-based Ebola vaccine was recently used to manage a potential laboratory exposure.

UR - http://www.scopus.com/inward/record.url?scp=77958597255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958597255&partnerID=8YFLogxK

U2 - 10.1002/rmv.661

DO - 10.1002/rmv.661

M3 - Article

C2 - 20658513

AN - SCOPUS:77958597255

VL - 20

SP - 344

EP - 357

JO - Reviews in Medical Virology

JF - Reviews in Medical Virology

SN - 1052-9276

IS - 6

ER -